Filcad P 6mg Injection

About

Filcad P 6mg Injection contains Pegfilgrastim, a pegylated form of recombinant human granulocyte colony-stimulating factor (G-CSF). It is primarily indicated to decrease the incidence of infection, manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Pegfilgrastim works by stimulating the production, maturation, and activation of neutrophils from bone marrow stem cells, thereby increasing neutrophil counts and reducing the risk of infection during chemotherapy-induced neutropenia.

The pegylation process extends the half-life of G-CSF, allowing for a single dose per chemotherapy cycle, which is more convenient than daily filgrastim injections. This sustained action helps maintain adequate neutrophil levels throughout the nadir period, significantly reducing the morbidity and mortality associated with severe neutropenia.

Uses

• Prevention of febrile neutropenia in cancer patients.
• Patients receiving myelosuppressive chemotherapy.
• Reduction of infection risk during chemotherapy.
• Stimulation of neutrophil production.

Directions For Use

Administered subcutaneously by a healthcare professional or trained patient. Typically given once per chemotherapy cycle.

Benefits

• Reduces incidence of febrile neutropenia.
• Decreases risk of chemotherapy-related infections.
• Convenient single dose per chemotherapy cycle.
• Supports chemotherapy dose intensity.
• Improves patient safety during treatment.
• Enhances neutrophil recovery.

Side Effects

• Bone pain
• Myalgia (muscle pain)
• Headache
• Fatigue
• Nausea
• Diarrhea
• Constipation
• Injection site reactions
• Splenomegaly (rare)
• Acute respiratory distress syndrome (rare)
• Glomerulonephritis (rare)
• Capillary leak syndrome (rare)

Safety Measures

• Alcohol - No specific interaction, but avoid excessive alcohol which can impact overall health during chemotherapy.
• Pregnancy - Use only if clearly needed; potential risks to the fetus should be weighed against maternal benefit.
• Breastfeeding - Not recommended; it is unknown if it passes into breast milk.
• Liver - No specific dose adjustment required for hepatic impairment.
• Kidney - No specific dose adjustment required for renal impairment.
• Lung - Monitor for pulmonary adverse reactions, including interstitial pneumonia; discontinue if severe symptoms occur.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.